Sutro Biopharma Inc expected to post a loss of 88 cents a share - Earnings Preview

Sutro Biopharma

26/03/2024 11:04

* Sutro Biopharma Inc  STRO.OQ   STRO.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 13
(estimated) for the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 17.7% decrease in revenue to $10.436 million from
$12.67 million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Sutro Biopharma Inc is
for a
loss of 88 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sutro
Biopharma
Inc is $12.00​, above​ its last closing price of $3.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.82      0.52      Beat    163.2
 Sep. 30 2023  -0.74       -0.74      -0.81     Missed  -10.1
 Jun. 30 2023  -0.75       -0.73      -0.64     Beat    12.6​
 Mar. 31 2023  -0.80       -0.81      -0.85     Missed  -4.8
 ​​Dec.        -0.61       -0.62      -0.68     Missed  -9.5
 31 2022                                                
 Sep. 30 2022  -0.75       -0.74      -0.37     Beat    49.9​
 Jun. 30 2022  -0.43       -0.46      -0.55     Missed  -19.2
 Mar. 31 2022  -0.77       -0.76      -0.84     Missed  -10.9
 This summary was machine generated March 26 at 11:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)